Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NJ1A
|
|||
| Former ID |
DNC008582
|
|||
| Drug Name |
Aloxistatin
|
|||
| Synonyms |
NSC694281; AC1L95AQ; SCHEMBL254426; CHEMBL1978255; CTK8C9289; ethyl(2s,3s)-3-[[1-(isopentylcarbamoyl)-3-methyl-butyl]carbamoyl]oxirane-2-carboxylate; NSC-694281; VC30685; NCI60_033765; ethyl (2S,3S)-3-[[4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate; 2-Oxiranecarboxylicacid,3-[[[(1S)-3-methyl-1-[[(3-methylbutyl)amino]carbonyl]butyl]amino]carbonyl]-,ethyl ester, (2S,3S)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Neurological disorder [ICD-11: 6B60] | Discontinued in Phase 3 | [1] | |
| Coronavirus infection [ICD-11: 1D92; ICD-10: B34.2] | Preclinical | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H30N2O5
|
|||
| Canonical SMILES |
CCOC(=O)C1C(O1)C(=O)NC(CC(C)C)C(=O)NCCC(C)C
|
|||
| InChI |
1S/C17H30N2O5/c1-6-23-17(22)14-13(24-14)16(21)19-12(9-11(4)5)15(20)18-8-7-10(2)3/h10-14H,6-9H2,1-5H3,(H,18,20)(H,19,21)/t12-,13-,14-/m0/s1
|
|||
| InChIKey |
SRVFFFJZQVENJC-IHRRRGAJSA-N
|
|||
| CAS Number |
CAS 88321-09-9
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:101381
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002441) | |||
| REF 2 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
| REF 3 | In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. | |||
| REF 4 | Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. J Biol Chem. 2007 Jul 20;282(29):20836-46. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.